Zoledronic acid therapy impacts risk and frequency of skeletal complications and follow-up duration in prostate cancer patients with bone metastasis

Current Medical Research and Opinion

Volumn 27, Issue 1, 2011, Pages 55-62

  Hatoum, Hind T ^a   Lin, Swu Jane ^a   Guo, Amy ^b   Lipton, Allan ^c   Smith, Matthew R ^d  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bone metastasis; Prostate; Prostatic neoplasms; Skeletal complication; Zoledronic acid

Indexed keywords

ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DISEASE; BONE METASTASIS; COHORT ANALYSIS; DRUG EFFECT; EVALUATION; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSTATE CANCER; RETROSPECTIVE STUDY; RISK REDUCTION; TIME;

AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; BONE NEOPLASMS; COHORT STUDIES; DIPHOSPHONATES; FOLLOW-UP STUDIES; HUMANS; IMIDAZOLES; INCIDENCE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK; TREATMENT OUTCOME;

EID: 78650408775     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2010.535511     Document Type: Article

References (26)

1. Saad F, Sternberg CN. Multidisciplinary management of bone complications in prostate cancer and optimizing outcomes of bisphosphonate therapy. Nat Clin Pract Urol 2007;4:S3-13
2. Yuen KK, Shelley M, Sze WM, et al. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev 2006; CD006250
3. Saad F, Chi K, Fleshner N. The role of bisphosphonates in the management of bone metastases in prostate cancer. Can J Urol 2004;11:2376-82
4. Groot MT, Boeken Kruger CGG, Pelger RCM, et al. Costs of prostate cancer metastatic to the bone, in the Netherlands. Eur Urol 2003;43:226-32
5. Reed SD, Radeva JI, Glendenning GA, et al. Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. J Urol 2004;171:1537-42
6. Lage MJ, Barber BL, Harrison DJ, et al. The cost of treating skeletal-related events in patients with prostate cancer. Am J Manag Care 2008;14:317-22
7. Guise TA, Chirgwin JM. Role of bisphosphonates in prostate cancer bone metastases. Semin Oncol 2003;30:717-23
8. Lattouf JB, Saad F. Preservation of bone health in prostate cancer. Curr Opin Support Palliat Care 2007;1:192-7
9. Novartis: Zometa® (zoledronic acid) Prescribing Information. East Hanover, NJ: Novartis Pharmaceuticals Corp 2008
10. Polascik TJ, Mouraviev V. Zoledronic acid in the management of metastatic bone disease. Ther Clin Risk Manag 2008;4:261-8
11. Saad F, Chen YM, Gleason DM, et al. Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases. Clin Genitourin Cancer 2007;5:390-6
12. SaadF, Gleason DM, Murray R, etal. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82
13. Addeo R, Nocera V, Faiola V, et al. Management of pain in elderly patients receiving infusion of zoledronic acid for bone metastasis: a single-institution report. Support Care Cancer 2008;16:209-14
14. Hoesl CE, Altwein JE. Biphosphonates in advanced prostate and renal cell cancer-current status and potential applications. Urol Int 2006;76:97-105
15. Hatoum HT, Lin SJ, Smith MR, et al. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 2008;113:1438-45
16. Rosen LS, Gordon D, Tchekmedyian S, etal. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003;21:3150-7
17. D'Agostino Jr RB, Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81
18. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83
19. Quan H, Sundararajan V, Halfon P et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care 2005;43:1130-9
20. Dreicer R. Current status of cytotoxic chemotherapy in patients with meta-static prostate cancer. Urol Oncol 2008;26:426-9
21. Saad F, Clarke N, Colombel M. Natural history and treatment of bone complications in prostate cancer. Eur Urol 2006;49:429-40
22. Aapro MS. Management of bisphosphonate treatment in clinical practice. Semin Oncol 2007;34:S28-32
23. Major PP, Cook RJ, Chen BL, et al. Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zoledronic acid in patients with bone metastases from solid tumors. Support Cancer Ther 2005;2: 234-40
24. Saad F, Lipton A. Clinical benefits and considerations of bisphosphonate treatment in metastatic bone disease. Semin Oncol 2007;34:S17-23
25. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zole-dronic acid in premenopausal breast cancer. N Engl J Med 2009;360:679-91
26. Zarogoulidis K, Boutsikou E, Zarogoulidis P, et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 2009;125:1705-9